Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).
Public ClinicalTrials.gov record NCT00523991. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24 Week, Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by HandiHaler Once-daily Plus PRN Albuterol (Salbutamol) vs. Placebo Plus PRN Albuterol (Salbutamol) in Chronic Obstructive Pulmonary Disease Subjects Naive to Maintenance Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18mcg of tiotropium inhalation capsules administered by Handihaler once daily plus Pro Re Nata (PRN) albuterol (salbutamol) vs. placebo plus PRN albuterol (salbutamol) in chronic obstructive pulmonary disease subjects naive to maintenance therapy.
Study identification
- NCT ID
- NCT00523991
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 457 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2007 (Type not available)
- Primary completion
- Jul 2010 (Actual)
- Completion
- Not listed
- Last update posted
- May 20, 2014
Started 2007
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.365.1003 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 205.365.1004 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 205.365.1098 Boehringer Ingelheim Investigational Site | Jasper | Alabama | — | — |
| 205.365.1023 Boehringer Ingelheim Investigational Site | Palo Alto | California | — | — |
| 205.365.1125 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 205.365.1024 Boehringer Ingelheim Investigational Site | Lexington | Kentucky | — | — |
| 205.365.1012 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 205.365.1086 Boehringer Ingelheim Investigational Site | Bloomington | Minnesota | — | — |
| 205.365.1006 Boehringer Ingelheim Investigational Site | Rochester | Minnesota | — | — |
| 205.365.1085 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 205.365.1010 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 205.365.1007 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 205.365.1080 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 205.365.1118 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 205.365.1033 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 205.365.1092 Boehringer Ingelheim Investigational Site | Kingsport | Tennessee | — | — |
| 205.365.1122 Boehringer Ingelheim Investigational Site | Clarksburg | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00523991, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2014 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00523991 live on ClinicalTrials.gov.